RDT

TSS Solutions Appoints Gary Ambrose as COO

Retrieved on: 
수요일, 1월 31, 2024
Technology, Other Defense, Engineering, Satellite, Telecommunications, Aerospace, Manufacturing, Government Technology, Defense, Multimedia, Lead, Electronics, Acorn, UAS, RADAR, AGC Aerospace & Defense, Freedom, Investment, Intelligence, Aviation, SATCOM, TSS, Navy, RDT, Woman, Risk management

View the full release here: https://www.businesswire.com/news/home/20240131551257/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240131551257/en/
    “Gary is bringing over three decades of aviation and defense expertise into TSS Solutions, and we welcome his leadership and drive to assist TSS with rapid technology insertions that add value to our existing RADAR portfolio,” says Don DiFrisco, TSS Solutions President and CEO.
  • TSS Solutions serves the global defense, telecommunications, and commercial industries.
  • The Company is committed to building innovative products and delivering world-class engineering and technical services to support customers' missions globally.
  • The men and women of TSS Solutions are proud to support the United States and its allies who protect national interests and preserve freedom and stability around the world.

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
일요일, 1월 7, 2024
NAMD, Conference, Gene family, Partnership, Neoplasm, Tumor microenvironment, IND, Hematopoietic stem cell transplantation, Radionuclide, CD47, Data, Myelodysplastic syndrome, Macrophage, Molecular Partners, HSC, Society, CHF, Novartis, ASH, COVID-19, DARPin, Toxicity, RDT, CD16, Stem cell, HSCT, Patient, Acute myeloid leukemia, Safety, Therapy, AML, DLL3, Health, SITC, Pharmaceutical industry

53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced it will present a business overview and provide its 2024 outlook at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.
  • In addition to these updates, Novartis has returned the rights to the ensovibep program, previously under investigation for the treatment of COVID-19, to Molecular Partners.

Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies

Retrieved on: 
금요일, 1월 5, 2024
Codevelopment, Protein, Partnership, Kidney, Molecular Partners, Novartis, DARPin, RDT, Patient, Carcinoma, Therapy, DLL3, Radiation, Pharmaceutical industry

This agreement represents the first co-development deal for Molecular Partners and Orano Med.

Key Points: 
  • This agreement represents the first co-development deal for Molecular Partners and Orano Med.
  • Both companies are developing additional radioligand therapy candidates in partnership with other companies, with Molecular Partners having announced its first collaboration with Novartis in December 2021.
  • Under the terms of the co-development agreement, Molecular Partner’s previously disclosed RDT target DLL3 (delta-like ligand 3) will be included in the partnership with Orano Med.
  • DLL3 will be exclusively developed by Molecular Partners and Orano Med as a RDT target.

Teal Group Predicts Worldwide Military UAS Spending of $258.7 Billion Over the Next Decade

Retrieved on: 
수요일, 1월 3, 2024
Unmanned combat aerial vehicle, Unmanned aerial vehicle, Ukrainians, UAS, ECM, Research, Vertical, Electronic countermeasure, SIGINT, UAV, SARS, RDT, Artillery, Growth, System, United States Army

Teal Group's 2023/2024 World Military Unmanned Aerial Systems Market Profile & Forecast estimates that UAS procurement funding will increase from the current worldwide level of just over $14 billion annually in 2024 to $23.1 billion in 2033, totaling $186.8 billion over the next 10 years.

Key Points: 
  • Teal Group's 2023/2024 World Military Unmanned Aerial Systems Market Profile & Forecast estimates that UAS procurement funding will increase from the current worldwide level of just over $14 billion annually in 2024 to $23.1 billion in 2033, totaling $186.8 billion over the next 10 years.
  • Military UAS research spending would add another $71.8 billion over the decade.
  • "We predict that the US will account for 81% of total military worldwide RDT&E spending on UAS technology over the next decade and 59% of military procurement," said Teal Group senior analyst Steve Zaloga.
  • Teal Group is an aerospace and defense market analysis firm based in Fairfax, Virginia, USA.

Mangoceuticals Launches MangoRx Mexico Subsidiary, Paving the Way for Over-the-Counter Retail of Erectile Dysfunction Line of Products in Latin America

Retrieved on: 
수요일, 12월 6, 2023
Marketing, EFI, ED, Oracle, Research, Certification, USD, Allianz, RDT, Pharmacy, OTC, Erectile dysfunction, Sony

Dallas, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated hair growth product (‘GROW’) and erectile dysfunction (ED) drug (‘Mango’), is excited to announce the establishment of its subsidiary, MangoRx Mexico, which will act as the lynchpin of the Company’s Mexican and expanded Latin American sales strategies for its Mango ED products.

Key Points: 
  • The Company has engaged one of the largest international law firms, Diaz Reus International Law Firm, to establish its subsidiary presence in Mexico.
  • “This has enormous implications for our growth trajectory going forward for several important reasons,” noted Jacob Cohen, MangoRx’s Co-Founder and CEO.
  • “First, ED medications - such as branded and generic Viagra (Sildenafil) and Cialis (Tadalafil) - are available to consumers over-the-counter in Mexico.
  • “The path from here to full launch of Latin American sales for MangoRx products is a top priority, and we look forward to providing updates very soon.”

3D Systems Receives FDA Clearance for NextDent® Base

Retrieved on: 
수요일, 11월 15, 2023
Nexus, Eye, Health Canada, RDT, NYSE, Prosthodontics, DDS, RPD, Patient, 3D Systems, FDA, Food and Drug Administration, Printing, Workflow, Heel, 3D, ROCK, Plaster, Medical device, 3D printing

NextDent Base is the third generation of the company’s denture base material for 3D printing and has excellent mechanical properties including high break resistance, and accurate and repeatable printability.

Key Points: 
  • NextDent Base is the third generation of the company’s denture base material for 3D printing and has excellent mechanical properties including high break resistance, and accurate and repeatable printability.
  • NextDent Base is truly comparable to conventional denture materials and provides patients with long-lasting, impact-resistant dentures.
  • Using NextDent Base as part of 3D Systems’ digital dental workflow is helping drive new levels of speed, productivity, efficiency, and precision while also providing opportunities to improve the patient experience.
  • “With the clearance of NextDent Base, we continue to add to our portfolio of dental 3D printing materials that are enabling dental laboratories and clinics to address a wide range of applications.

Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)

Retrieved on: 
화요일, 11월 14, 2023
DARPin, RDT, Immune system, Senior, Tetra, Service provider, ASH, CD70, CD40, Patient, Tumor microenvironment, Immunotherapy, Neoplasm, Therapy, FAP, Exposition, Novartis, CD33, Cancer, Trial of the century, SITC, Toxic epidermal necrolysis, Partnership, AML, Society, Molecular Partners, Myelodysplastic syndrome, CD123, Cell, CD3, Medical imaging, Vaccine, Research, CONCORD

The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.

Key Points: 
  • The presentation will focus on the multiple ways Molecular Partners has designed DARPins to activate the immune system against cancer only under certain conditions.
  • This conditional activation is intended to focus immune attack more specifically against tumor cells and minimize damage to healthy cells, a major challenge for current oncology drugs and development efforts.
  • The SWITCH-DARPin platform, a versatile novel DARPin design for conditionally triggering an immune cell attack only in the presence of defined tumor antigens.
  • The portfolio of RDT candidates represent a unique delivery system for radioactive payloads to solid tumors and has significantly expanded the company’s work in oncology therapeutics.

United States (US) Department of Defense (DoD) Cybersecurity Contracting Research Study, FY 2023: Research, Development, Test, and Evaluation (RDT&E); Procurement; and Services - ResearchAndMarkets.com

Retrieved on: 
화요일, 12월 5, 2023
Technology, Defense, Security, Other Defense, Environment, Research, RDT, Organization, FY, Outline, Arms industry

The purpose of this study is to discuss the leading DoD cybersecurity contractors and technology areas of interest.

Key Points: 
  • The purpose of this study is to discuss the leading DoD cybersecurity contractors and technology areas of interest.
  • This research service focuses on the United States (US) Department of Defense (DoD) cybersecurity contracting information for research, development, test, and evaluation (RDT&E); procurement; and services.
  • The data and insight provided are fiscal (FY) 2023 DoD contracting information.
  • The main goals are to understand the current state of the DoD cybersecurity competitive environment and point out both high-spending areas and opportunities to participate in the DoD cybersecurity market.

United States (US) Department of Defense (DoD) Cybersecurity Contracting Study FY 2023 with Commentary Regarding Competitive Firms and Contracting Trends

Retrieved on: 
화요일, 12월 5, 2023
Environment, Research, RDT, Organization, FY, Outline, Arms industry

The purpose of this study is to discuss the leading DoD cybersecurity contractors and technology areas of interest.

Key Points: 
  • The purpose of this study is to discuss the leading DoD cybersecurity contractors and technology areas of interest.
  • This research service focuses on the United States (US) Department of Defense (DoD) cybersecurity contracting information for research, development, test, and evaluation (RDT&E); procurement; and services.
  • This study will outline and provide commentary regarding competitive firms and contracting trends.
  • The main goals are to understand the current state of the DoD cybersecurity competitive environment and point out both high-spending areas and opportunities to participate in the DoD cybersecurity market.

HII Features Platforms, People, Technologies in "Delivering the Advantage" Campaign

Retrieved on: 
목요일, 11월 2, 2023
Aircraft, LVC, CVN, U.S. Department of Defense Strategy for Operating in Cyberspace, NYSE, HII, Life, Chad, U.S. Navy type commands, Ship, Workforce, Indian Head Naval Surface Warfare Center, Acquisition, United States Department of the Air Force, RDT, Artificial intelligence, United States Department of the Army, Ingalls, ISR, Machine learning, Newport News Shipbuilding, Cyber Security and Information Systems Information Analysis Center, Freedom, Vertical, Culture, Navy, Defense, AIC, Gasoline, Arms industry, Management, United States Navy, D.C

The leading provider of live, virtual, constructive (LVC) training for the U.S. military?

Key Points: 
  • The leading provider of live, virtual, constructive (LVC) training for the U.S. military?
  • The employer of more than 44,000 workers across 39 states, and the largest industrial employer in both Virginia and Mississippi?
  • The answer is HII (NYSE: HII), and a new targeted advertising campaign showcases the breadth of HII’s platforms, technologies and solutions across domains and services, in support of HII’s mission to deliver the advantage to its national defense customers.
  • “HII is dedicated to meeting the dynamic requirements of the U.S. Department of Defense and our international allies,” HII President and CEO Chris Kastner said.